Miniatura

Fitxers

tlcr-14-04-1254.pdf (621.86 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-04-21

Llicència de publicació

cc-by-nc-nd (c) AME Publishing Company, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222223

Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.21037/tlcr-2024-1146

Resum

Background: Geographic variability in epidermal growth factor receptor (EGFR) mutation rates in early-stage non-small cell lung cancer (NSCLC) has been reported. However, the frequency of EGFR mutations in patients with early-stage resected NSCLC in Spain has not been previously investigated. We aimed to determine the prevalence of EGFR mutations in patients with early-stage resected NSCLC in Spain. Methods: This was an observational, multicenter, cross-sectional study. Sensitizing EGFR mutations were assessed via real-time polymerase chain reaction (PCR)-based molecular analysis with the IdyllaTM TM EGFR Mutation Test , next-generation sequencing (NGS) analysis with the OncomineTM TM Precision Assay. Results: A total of 172 patients with surgically resected non-squamous NSCLC were analysed. Median age was 67.5 years , 57.6% were male, 96.5% had adenocarcinoma histology and 65% had stage IA/IB. EGFR mutations were found using IdyllaTM TM EGFR Mutation Test in 25 patients out of 172 patients (14.5%), which consisted of exon 19 deletion in 13 patients (7.6%), exon 21 L858R point mutation in 11 (6.4%), and exon 20 mutation (T790M) in 1 (0.6%) patient. The OncomineTM TM test was conducted in 128 patients, which detected exon 19 deletions in 10 patients (7.8%), exon 21 mutations in 10 patients (7.8%), and exon 20 insertions in 5 (3.9%) patients. The OncomineTM TM test was able to detect concurrent mutations in tumor suppressor genes ( TP53, PI3KCA, CDKN2A, PTEN) ) and another actionable alteration beyond EGFR, , such as mutations in KRAS G12C (22%), ERBB2 (6%), METex14 (2%), BRAF V600E (2%) and ALK and ROS1 fusions (2%, each). Conclusions: The prevalence of EGFR mutations in early stage (IA-IIIB), resectable, non-squamous NSCLC observed in our study is consistent with that reported in advanced NSCLC in Spain. Molecular testing is crucial in early-stage NSCLC and can be performed either with single-gene testing or NGS.

Matèries

Càncer de pulmó, Mutació (Biologia), Oncogens

Matèries (anglès)

Lung cancer, Mutation (Biology), Oncogenes

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

VARELA RODRÍGUEZ, Mar, TEIXIDÓ, Cristina, ÁLVAREZ FERNÁNDEZ, Carlos, ARASANZ, Hugo, PERALTA MUÑOZ, Sergio, LÁZARO QUINTELAS, Martín, CALVO, Virginia, ÁLVAREZ ÁLVAREZ, Rosa, BAENA, Javier, VALDIVIA BAUTISTA, Javier, ARRIOLA APERRIBAY, Edurne, BERNABÉ, Reyes, ISLA, Dolores, CAMACHO, María del carmen, MASSUTI, Bartomeu, BLASCO, Ana, GARCÍA MANRIQUE, Teresa, COBO, Manuel, CAMPAYO GUILLAUMES, Marc, HIJAZO PECHERO, Sara, CALLEJO, Ángel, DOMÍNGUEZ, Marta, NADAL, Ernest. Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study. _Translational Lung Cancer Research_. 2025. Vol. 14, núm. 4, pàgs. 1254-1265. [consulta: 21 de gener de 2026]. ISSN: 2226-4477. [Disponible a: https://hdl.handle.net/2445/222223]

Exportar metadades

JSON - METS

Compartir registre